Xyphos Biosciences Inc., a wholly owned subsidiary of Astellas Pharma Inc., and Kelonia Therapeutics Inc. have entered into a research collaboration and license agreement to develop novel immuno-oncology therapeutics.
Intellia Therapeutics Inc. and Recode Therapeutics Inc. have established a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis.
Vantai Inc. and Bristol Myers Squibb Co. have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.
Ono Pharmaceutical Co. Ltd. has entered into an option and collaboration agreement with Numab Therapeutics AG to develop and commercialize a novel multispecific macrophage engager, NM-49, in oncology.
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration and option agreement with Shattuck Labs Inc. to generate bifunctional fusion proteins.
Valirx plc has signed an over-arching agreement with the University of Dundee and its drug discovery unit (DDU) to access research relating to novel therapeutic candidates.
Autolus Therapeutics Inc. has picked up plenty of financial momentum, about $600 million worth, in its runup to a November 2024 PDUFA date for its CD19 CAR T therapy. Helping propel that momentum is Biontech SE, another CAR T therapy developer. For $50 million cash, Biontech bought the rights to use Autolus’ manufacturing and commercial infrastructure in the U.K. so it can advance its CAR T-cell BNT-211 program in the clinic.
The University of Texas MD Anderson Cancer Center and C-Biomex Ltd. have announced a strategic research collaboration agreement to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
RSS
